New study tracks birth defect risks in MS drug BRIUMVI during pregnancy

NCT ID NCT06433765

Recruiting now Knowledge-focused Sponsor: TG Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This registry study follows pregnant women with multiple sclerosis (MS) who have taken BRIUMVI, comparing them to those who haven't taken the drug. The goal is to see if BRIUMVI increases the risk of major birth defects. Researchers will enroll about 728 participants across two groups to gather real-world safety data.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could provide clearer safety data on BRIUMVI use during pregnancy, helping doctors and patients make informed decisions.
What could go wrong: This is an observational registry, not a treatment trial, so it won't test new therapies. Results depend on accurate reporting and may take years to gather enough data.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

BRIUMVI® Pregnancy Registry Virtual Research Coordination Center
RECRUITING

Wilmington, North Carolina, 28401-3331, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.